This was sent via email today. Jamie ————— May 1, 2024 Anne Yu Director for Global Pandemic Preparedness Development, Global Health and Humanitarian Response, National Security Council Staff, Executive Office of the President Dear Anne Yu, I’m guessing you are… Continue Reading
This is an annex to the document: KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024, which is available as a PDF here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft Annex on Investor-State Dispute… Continue Reading
PDF version is available here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024 James Love Knowledge Ecology International April 28, 2024, revised April 29, 2024 Introduction… Continue Reading
A_inb9_3Rev1-en22april2024 There are seven references to “mutually agreed” terms in the text relating to intellectual property and knowledge sharing, and some of these can and will be used to intimidate developing countries from using mandatory measures. The United States used… Continue Reading
Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading
To get an idea of the challenges of getting agreement on the WHO pandemic accord text, consider the state of just one article on Saturday, March 23, 2024. Article 11 has 6 paragraphs on technology transfer. According to an analysis… Continue Reading
The REVISED Draft of the negotiating text of the WHO Pandemic Agreement, March 7, 2024 INB_DRAFT_7March2024 A few quick word counts: mutually agreed 1 incentivize, 4 times Voluntary, 5 times take measures, 8 times Transparent or transparency, 8 cooperate 9… Continue Reading
These are KEI’s post hearing responses to three questions regarding USTR’s Special 301 list. KEI-Special301-28Feb2024 One question was a follow up to KEI’s testimony that USTR should develop a policy on the trade related aspects of biomedical R&D that does… Continue Reading